SCHEMBL24599202

SCHEMBL24599202

COC(=O)c1cc2c(=O)[nH]c(-c3ccccc3F)nn2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
ALDH1A1 P00352 4/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TNKS O95271 1/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38
MAPT P10636 1/20 0.38
ERCC1 P07992 1/20 0.38
FEN1 P39748 1/20 0.38
ERCC4 Q92889 1/20 0.38
HPGD P15428 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HSD17B10 Q99714 1/20 0.38
IDO1 P14902 1/20 0.37
F2RL3 Q96RI0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24599204 0.88 KDM4A (0.42) ALDH1A1KMT2AKDM4ETNKSTSHR
SCHEMBL24599203 0.80 KDR (0.41) MAPK14TNKSMAPTPARP1ADORA3
SCHEMBL23361516 0.76 POLB (0.43) MAPK14NPC1RAB9AALDH1A1KMT2A
SCHEMBL15527637 0.75 TNKS (0.47) MAPK14NPC1RAB9AALDH1A1KDM4E
SCHEMBL23361611 0.75 TNKS (0.38) MAPK14ALDH1A1KMT2AKDM4ETNKS
SCHEMBL16611551 0.74 ALKBH5 (0.44) KMT2ASMN1; SMN2TNKSMAPTERCC1
SCHEMBL16731004 0.74 S1PR1 (0.37) KDM4ESMN1; SMN2MAPTHSD17B10
SCHEMBL23140215 0.72 PIK3CA (0.42)
SCHEMBL15604819 0.71 TNKS (0.48) MAPK14NPC1RAB9AALDH1A1KDM4E
SCHEMBL16611005 0.71 S1PR1 (0.36) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228500-A1 THERAPEUTIC CONJUGATES TOTUS MEDICINES INC. 2024-07-11 US disclosed
US-12029791-B2 Therapeutic conjugates TOTUS MEDICINES INC. (US) 2024-07-09 US disclosed
US-20220387603-A1 THERAPEUTIC CONJUGATES TOTUS MEDICINES INC. 2022-12-08 US disclosed
US-20220211855-A1 THERAPEUTIC CONJUGATES TOTUS MEDICINES INC. 2022-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12029791-B2 Therapeutic conjugates CD47, CD44, EPCAM MAPK14 4714/4885NPC1 686/4885RAB9A 1120/4885
US-20240228500-A1 THERAPEUTIC CONJUGATES CD47, CD44, EPCAM MAPK14 4714/4885NPC1 686/4885RAB9A 1120/4885
US-20220387603-A1 THERAPEUTIC CONJUGATES CD47, CD44, EPCAM MAPK14 4714/4885NPC1 686/4885RAB9A 1120/4885
US-20220211855-A1 THERAPEUTIC CONJUGATES CD47, CD44, EPCAM MAPK14 4714/4885NPC1 686/4885RAB9A 1120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.